Volume 26, Number 10—October 2020
Research
Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland
Andreas F. Widmer, Reno Frei, Ed J. Kuijper, Mark H. Wilcox, Ruth Schindler, Violeta Spaniol, Daniel Goldenberger, Adrian Egli, Sarah Tschudin-Sutter
, and Kuijper
, and Kuijper
Table 3
Reported and measured detection and testing rates of toxigenic Clostridioides difficile, Switzerland, 2015*
| Institutions and testing methods | Reported rate/10,000 patient bed-days | Measured rate/10,000 patient bed-days, winter (range) | Measured rate/10,000 patient bed-days, summer (range) | Mean measured rate/10,000 patient bed-days (range) | Testing rate/10,000 patient bed-days (range) |
|---|---|---|---|---|---|
| All institutions | 3.8 (0–11) | 67.5 (0–3,202) | |||
| EIA | 6.4 (0–387) | 5.7 (0–475) | 6.1 (0–475) | ||
| NAAT |
11.4 (0–387) |
7.1 (0–475) |
9.3 (0–475) |
||
| Children’s hospitals | 1.1 (0.4–1.1) | 22.5 (7.0–46.7) | |||
| EIA | 33.7 (0–73) | 0 | 16.9 (0–73) | ||
| NAAT | 67.3 (0–99) | 0 | 33.6 (0–99) |
EIA, enzyme immuno assay; GDH, glutamate dehydrogenase; NAAT, nucleic acid amplification tests.
Page created: July 24, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.